ko en en fi es en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en de en de en de en en de en de en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en la nl en en en de fr en la en en it de fr fr en la en en it ca fr de it la de en en oc fr de fr la eu en en nl fr fr la la eu en en de fr sv en la nl en en fr fr en en la de en en fr fr en en sv fr de de fr en en pt en en fa fr en en en ca en fr sv en en en it ca fr en en en it de fr en en en en fr fr en en en en fr de en en en en fr de en en fi en de fr en en en en fr sv en en fr en fr en en en it en fr en en sv fr de de en ceb ceb en fa en en hi ko hu en en en id tr en en en eo en ms en it it hi ko ko hu en en
Stay signed in Forgot password?
Not a member yet? Register now
Leading Company in Global Gene Therapy
For the development of mankind and a better quality of life
Developing Next Generation CAR-T Therapy
Cellengene is biopharmaceutical company dedicated to the development for CAR-T therapy targeting refractory solid tumors. Our goal is to develop
"Off-the-Shelf" CAR-T therapy that can selectively attack cancer cells  using immune cell derived from healthy people. In order to cure pancreatic cancer, we plan to use gammadelta T cell and induced pluripotent stem cell (iPSC) platform. Furthermore, we will be enabled to cure ovarian cancer, mesothelioma and will become a global company to help many patients who are suffering from refractory cancers.
We belive next generation CAR-T therapy will give hope to many patients and lead them to have happier and healthier life.
▷ International patent application (Singapore)
▷ International patent application (U.S, Japan, Europe, Australia, Canada, China)
▷ Headquarter relocation to Institut Pasteur Korea
▷ Investment attraction from SJ Investment Partners
▷ Selected as a Bio Core Facility construction project in Institut Pasteur Korea
▷ Investment attraction from Soorim Venture Capital Co., Ltd.
▷ LMO Safety Management Level 2 Certificate
▷ Selected as a TIPS-linked business (Start-up commercialization, overseas marketing)
▷ Selected as TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup)
▷ Attracting angel matching investment from Korea Venture Investment Co., Ltd.
▷ Designated as Seoul Bio Hub All-In-One (Selection of mentor consulting support project)
▷ Approval of pre-sale to the National Stem Cell Bank under the National Institute of Health
▷ Acquired Kingsley Ventures Inc. VC funding
▷ Venture company Certification
▷ Moved into Seoul Biohub
▷ Small business Certification
▷ Established enterprise affiliated research institute
▷ Commissioned research agreement with Osong Medical Innovation Foundation (K-Bio)
▷ Established Cellengene Inc.
▷ Biohealth Innovation Start-up Members (Moved into Yonsei Bongrae Building)
CAR-T therapy is one of the immunotherapy, including genetically modified T cell expressing unique receptor "Chimeric Antigenic Receptor" .  This unique receptor binds to certain protein on patient's cancer cells and selectively attack them.  In current situation, FDA approval were granted to 5 types of treatment targeting hematological malignancies, including “Kymriah” from Novartis and “Yescarta” from Gilead.  There are many ongoing researches, developments and clinical stages on CAR-T therapy but no succeed case appears yet.
In general, there are two ways to manufacture CAR-T therapy.  Autologous CAR-T  is personalized therapy that does not incur GvHD.  Because it is  derived from patient's own cell and reinjected to the patient. However, manufacturing process takes at least 3 weeks and costs are very expensive. Allogenic CAR-T is universal therapy that require genetically engineering process and mass production is available. Manufacturing process takes approximately 1 week and costs are lower than autologous CAR-T production. Therefore, immediate injection is available for hundreds of patients.
Preventing GvHD and overcoming tumor microenvironment(TME) are key factors to develop allogenic CAR-T therapy. In order to overcome these certain problems, TCR is knockout using CRISPER/CAS9 gene editing technology and immune check receptor, PD-1, is  knockdown to induce T cell activation and attack cancer cell continuously.
all title content name
Beautiful design and layout...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus et nisl ex. Maecenas dignissim volutpat efficitur. Nullam hendrerit dui mattis sapien pulvinar blandit.
Excellent work! Great presentation!
Quisque ut urna tempus, aliquam libero vitae, viverra lacus. Nunc dictum viverra elit, sed tincidunt turpis tincidunt vel.
Awesome work..really very inspirational job
Etiam ut sapien mauris. Nullam molestie elit sem, accumsan lacinia eros condimentum in. Morbi varius turpis in sapien rhoncus, at sagittis massa accumsan.
Aenean malesuada non libero a auctor
Vivamus sollicitudin leo quis suscipit cursus. Fusce tristique justo vitae risus elementum, sit amet maximus lectus finibus. Vivamus tristique tristique turpis. Vivamus quam mi, imperdiet ac orci id, facilisis dictum massa Nunc condimentum molestie risus. Nullam mollis quam...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus et nisl ex. Maecenas dignissim volutpat efficitur. Nullam hendrerit dui mattis sapien pulvinar blandit.
Etiam ut sapien mauris
Quisque ut urna tempus, aliquam libero vitae, viverra lacus. Nunc dictum viverra elit, sed tincidunt turpis tincidunt vel. Praesent eget metus sapien. Maecenas viverra quam justo, eu rhoncus elit congue non.
Excellent work! Great presentation!
Etiam ut sapien mauris. Nullam molestie elit sem, accumsan lacinia eros condimentum in. Morbi varius turpis in sapien rhoncus, at sagittis massa accumsan.
Beautiful design and layout...
Vivamus sollicitudin leo quis suscipit cursus. Fusce tristique justo vitae risus elementum, sit amet maximus lectus finibus. Vivamus tristique tristique turpis. Vivamus quam mi, imperdiet ac orci id, facilisis dictum massa Nunc condimentum molestie risus. Nullam mollis quam...
all title content name
Frequently asked question about this pages and delevery process while ordered post didn't arrive 7
Good design.I will be glad if you see my latest work.
awesome work..really very inspirational job.congrats
Beautiful design and layout.. Great job
Amazing work one really feels like in a stone age. Impressive!
Unbelievable divat not dive project itself is awesome but it's presentation here... congratulations!
Excellent work! Great presentation!
od design.I will be glad if you see my latest work.
Beautiful design and layout.. Great job
Amazing work one really feels like in a stone age. Impressive!
INQUIRY FOR JOB POSITIONS
개인정보 수집 및 이용동의 / 약관 보기
3rd Floor, Research Building, Institut Pasteur Korea                                                   16 Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si,
Research Building Rm 204, Seoul Bio Hub
117-3 Hoegi-ro, Dongdaemun-gu, Seoul,
Republic of Korea, 02455
개인정보 수집 및 이용 동의 / 약관 보기
개인정보 수집 및 이용 동의 ■ 개인정보 수집목적 및 이용목적 문의 및 메시지 접수 ■ 수집하는 개인정보 항목 성명, 이메일, 주소 등 ■ 개인정보의 보유기간 및 이용기간 관계 법령의 규정에 따라 귀하의 개인정보를 보존할 의무가 있는 경우가 아닌 한, 회사는 위의 수집 및 이용목적을 달성할 때까지 귀하의 개인정보를 보유 및 이용합니다. * 귀하는 위와 같은 일반 개인정보의 수집 및 이용을 거부할 수 있습니다. 다만, 일반 개인정보의 필수적 수집 및 이용에 동의하지 않을 경우 문의 및 메시지 서비스 이용이 불가능합니다.
BROWSE FILES...    Max upload file size : 1000M